Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly

Abstract

Several cardiovascular effects have been attributed to carfilzomib in the recent literature. These side effects must be recognized promptly by treating physicians and pharmacists. Special attention is required in patients with pre-existing cardiac conditions, liver function abnormalities and/or advanced age. This is the first report of a severe left atrial enlargement due to carfilzomib use in the setting of multiple myeloma. This condition improved dramatically seven months after cessation of carfilzomib. The authors discuss further various cardiac and vascular abnormalities linked with carfilzomib in the medical literature. Prompt withdrawal of this agent is essential in these cases as it may prevent dismal outcomes.

PMID: 30636528 [PubMed - indexed for MEDLINE]

15:18

Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:18

In reply to this message

pubmed: caandvteortroorpul

ASCO updated recommendations for preventing and treating VTE in adults with cancer.

Related Articles

ASCO updated recommendations for preventing and treating VTE in adults with cancer.

Ann Intern Med. 2020 Jan 21;172(2):JC2

Authors: Stockler MR

PMID: 31958816 [PubMed - in process]

15:18

Photo

Not included, change data exporting settings to download.

256×256, 6.0 KB

15:18

In reply to this message

pubmed: caandvteortroorpul

How I treat cancer-associated thrombosis.

Related Articles

How I treat cancer-associated thrombosis.

ESMO Open. 2020 Jan;5(1):

Authors: Moik F, Pabinger I, Ay C